ArticleHealth behavior research2026
Oregon's Psilocybin Services: A Summary and Public Health Commentary.
Article in Health behavior research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Psilocybin is a federally illegal psychedelic substance that carries positive (e.g., treatment for mood disorders) and negative (e.g., emotional distress) consequences. In 2020, Oregon legalized psilocybin for adult use (21+) at the state level, restricted to designated service centers. In Fall 2024 and Spring 2026, we summarized and compared Oregon's legal/regulatory psilocybin context and highlighted public health considerations. We found there are no limits on the number of licenses that can be issued, and there are mandated trainings to obtain facilitator licensure (e.g., 120/128 hours of instruction in 2024/2026, requiring a test score of 75% [unlimited number of testing attempts]). Regulations specify manufacturing rules, including allowable ingredients and testing for contaminants and concentration. One serving includes 25mg of psilocybin analyte; two servings per person are allowed. Labeling guidelines are provided (e.g., safety warnings and no youth-oriented wording). We identified the presence of psilocybin-related websites that were not age-gated. We found pricing information related to administration ($15-$3,500/person) and facilitator training ($3,000-$14,175). Given the inability to limit the number of psilocybin licensees, the number of service centers is likely to increase. Since Oregon psilocybin services do not license training programs, and given the unlimited number of testing attempts allowed, there may be issues ensuring individuals have adequately acquired the necessary knowledge. Longitudinal research is needed to assess the health impact of these programs and the long-term impacts of psilocybin use.
Indexed as
Identifiers
42428139PMC13348737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.